Detalhe da pesquisa
1.
[177Lu]Lu-PSMA-617 plus enzalutamide in patients with metastatic castration-resistant prostate cancer (ENZA-p): an open-label, multicentre, randomised, phase 2 trial.
Lancet Oncol
; 25(5): 563-571, 2024 May.
Artigo
em Inglês
| MEDLINE | ID: mdl-38621400
2.
ASPiRATION: Australian observational cohort study of comprehensive genomic profiling in metastatic lung cancer tissue.
Future Oncol
; 20(7): 361-371, 2024 Mar.
Artigo
em Inglês
| MEDLINE | ID: mdl-37767626
3.
Testosterone suppression plus enzalutamide versus testosterone suppression plus standard antiandrogen therapy for metastatic hormone-sensitive prostate cancer (ENZAMET): an international, open-label, randomised, phase 3 trial.
Lancet Oncol
; 24(4): 323-334, 2023 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-36990608
4.
INTEGRATE II: randomised phase III controlled trials of regorafenib containing regimens versus standard of care in refractory Advanced Gastro-Oesophageal Cancer (AGOC): a study by the Australasian Gastro-Intestinal Trials Group (AGITG).
BMC Cancer
; 23(1): 180, 2023 Feb 22.
Artigo
em Inglês
| MEDLINE | ID: mdl-36814222
5.
Enzalutamide with Standard First-Line Therapy in Metastatic Prostate Cancer.
N Engl J Med
; 381(2): 121-131, 2019 07 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-31157964
6.
MONARCC: a randomised phase II study of panitumumab monotherapy and panitumumab plus 5-fluorouracil as first-line therapy for RAS and BRAF wildtype metastatic colorectal cancer: a study by the Australasian Gastrointestinal Trials Group (AGITG).
BMC Cancer
; 21(1): 932, 2021 Aug 18.
Artigo
em Inglês
| MEDLINE | ID: mdl-34407800
7.
AGITG MASTERPLAN: a randomised phase II study of modified FOLFIRINOX alone or in combination with stereotactic body radiotherapy for patients with high-risk and locally advanced pancreatic cancer.
BMC Cancer
; 21(1): 936, 2021 Aug 19.
Artigo
em Inglês
| MEDLINE | ID: mdl-34412605
8.
REZOLVE (ANZGOG-1101): A phase 2 trial of intraperitoneal bevacizumab to treat symptomatic ascites in patients with chemotherapy-resistant, epithelial ovarian cancer.
Gynecol Oncol
; 161(2): 374-381, 2021 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-33637349
9.
ENZA-p trial protocol: a randomized phase II trial using prostate-specific membrane antigen as a therapeutic target and prognostic indicator in men with metastatic castration-resistant prostate cancer treated with enzalutamide (ANZUP 1901).
BJU Int
; 128(5): 642-651, 2021 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-34028967
10.
Durvalumab with first-line chemotherapy in previously untreated malignant pleural mesothelioma (DREAM): a multicentre, single-arm, phase 2 trial with a safety run-in.
Lancet Oncol
; 21(9): 1213-1223, 2020 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-32888453
11.
Challenges of international oncology trial collaboration-a call to action.
Br J Cancer
; 121(7): 515-521, 2019 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-31378784
12.
"As Long as You Ask": A Qualitative Study of Biobanking Consent-Oncology Patients' and Health Care Professionals' Attitudes, Motivations, and Experiences-the B-PPAE Study.
Oncologist
; 24(6): 844-856, 2019 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-30413662
13.
Protocol for the P3BEP trial (ANZUP 1302): an international randomised phase 3 trial of accelerated versus standard BEP chemotherapy for adult and paediatric male and female patients with intermediate and poor-risk metastatic germ cell tumours.
BMC Cancer
; 18(1): 854, 2018 Aug 29.
Artigo
em Inglês
| MEDLINE | ID: mdl-30157803
14.
Cell-free DNA in plasma and ascites as a biomarker of bevacizumab response- a translational research sub-study of the REZOLVE (ANZGOG-1101) clinical trial.
Transl Oncol
; 43: 101914, 2024 May.
Artigo
em Inglês
| MEDLINE | ID: mdl-38417292
15.
A Phase II trial of alternating osimertinib and gefitinib therapy in advanced EGFR-T790M positive non-small cell lung cancer: OSCILLATE.
Nat Commun
; 15(1): 1823, 2024 Feb 28.
Artigo
em Inglês
| MEDLINE | ID: mdl-38418463
16.
CTLA4 protects against maladaptive cytotoxicity during the differentiation of effector and follicular CD4+ T cells.
Cell Mol Immunol
; 20(7): 777-793, 2023 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-37161048
17.
NUTMEG: A randomized phase II study of nivolumab and temozolomide versus temozolomide alone in newly diagnosed older patients with glioblastoma.
Neurooncol Adv
; 5(1): vdad124, 2023.
Artigo
em Inglês
| MEDLINE | ID: mdl-37841696
18.
Multi-Arm GlioblastoMa Australasia (MAGMA): protocol for a multiarm randomised clinical trial for people affected by glioblastoma.
BMJ Open
; 12(9): e058107, 2022 09 14.
Artigo
em Inglês
| MEDLINE | ID: mdl-36104135
19.
Protocol of DREAM3R: DuRvalumab with chEmotherapy as first-line treAtment in advanced pleural Mesothelioma-a phase 3 randomised trial.
BMJ Open
; 12(1): e057663, 2022 Jan 25.
Artigo
em Inglês
| MEDLINE | ID: mdl-35078853
20.
Results of PD-L1 Analysis of Women Treated with Durvalumab in Advanced Endometrial Carcinoma (PHAEDRA).
Cancers (Basel)
; 15(1)2022 Dec 30.
Artigo
em Inglês
| MEDLINE | ID: mdl-36612250